BIGBEAR
PHARMACEUTICALS
Ivosidenib can reduce the production of the oncogenic metabolite 2-HG by selectively targeting and inhibiting the activity of the mutant IDH1 enzyme.
AuthenticGuaranteeFast DeliveryPrivacy Agios, a leading US-based cancer biopharmaceutical company and a pioneer in cellular metabolic therapies for cancer and rare genetic diseases, recentl···【Read More】
Update: 25 Mar,2026Source: Haiou HealthViews: 74
The U.S. Food and Drug Administration (FDA) has approved TIBSOVO (ivosidenib) for the treatment of relapsed or refractory adult acute myeloid leukemia···【Read More】
Update: 25 Mar,2026Source: Haiou HealthViews: 74
In 2021, Agios presented a comprehensive analysis of final data from the global Phase 3 ClarIDHy trial of the targeted anticancer drug ivosidenib (TIB···【Read More】
Update: 25 Mar,2026Source: Haiou HealthViews: 74
On May 25, 2022, Servier announced that the U.S. FDA had approved ivosidenib (Tibsovo) in combination with azacitidine for the treatment of newly diag···【Read More】
Update: 25 Mar,2026Source: Haiou HealthViews: 74
According to a press release from Servier Pharmaceuticals on October 24, the US Food and Drug Administration (FDA) announced that its IDH1 inhibitor T···【Read More】
Update: 25 Mar,2026Source: Haiou HealthViews: 70
According to a press release from Servier Pharmaceuticals, the U.S. Food and Drug Administration (FDA) has accepted and granted priority review to the···【Read More】
Update: 25 Mar,2026Source: Haiou HealthViews: 71
Copyright2024@ BIGBEAR All right reserved BIGBEAR
